ABSTRACT
The present report describes development of hexamethonium complexes based on fullerene C60. Hexamethonium has a limited penetration into CNS and therefore can antagonize central effects of nicotine only when given at high doses. In the present studies conducted in laboratory rodents, intraperitoneal administration of hexamethonium-fullerene complexes blocked effects of nicotine (convulsions and locomotor stimulation). When compared to equimolar doses of hexamethonium, complexes of hexamethonium with derivatives of fullerene C60 were 40 times more potent indicating an enhanced ability to interact with central nicotine receptors. Thus, fullerene C60 derivatives should be explored further as potential carrier systems for polar drug delivery into CNS.
Subject(s)
Brain/drug effects , Fullerenes/pharmacokinetics , Hexamethonium Compounds/pharmacokinetics , Nicotinic Antagonists/pharmacokinetics , Aminocaproates/chemistry , Animals , Anticonvulsants/chemistry , Anticonvulsants/pharmacokinetics , Brain/metabolism , Dose-Response Relationship, Drug , Fullerenes/administration & dosage , Fullerenes/chemistry , Hexamethonium Compounds/administration & dosage , Hexamethonium Compounds/chemistry , Locomotion/drug effects , Male , Mice , Nicotine , Nicotinic Antagonists/administration & dosage , Nicotinic Antagonists/chemistry , Rats, Wistar , Seizures/drug therapyABSTRACT
AIM: To adopt and validate the Straub tail reaction (SR) for comparative assessment of spastic effects of serotonergic compounds. MATERIAL AND METHODS: To measure the muscle relaxant activity, the morphine-induced Straub-tail assay was used. SR was graded according to modified intensity-score basis in a scale decribed by Kameyama et al. (1978). Subcutaneous injections of different doses of morphine (10-60 mg/kg) induced a dose-dependent SR with maximum response obtained 15-30 min after the morphine administration. RESULTS AND CONCLUSION: The centrally acting muscle relaxant baclofen (3-10 mg/kg) reduced SR induced by morphine (40 mg/kg) at all used doses; tizanidine decreased the intensity of SR at highest doses tested (0.6 and 1 mg/kg). Dantrolene (20-100 mg/kg), a peripherally acting muscle relaxant, did not affect SR. Effects of serotonergic agents depended on the specific mechanism of action. SR appears to be available for rapid evaluation of the effect of antispasticity drugs.
ABSTRACT
Catechol-O-methyltransferase (COMT) remains an important regulatory element in prefrontal cortex dopamine homeostasis. The literature data suggest that individual differences in COMT activity (Val158Met polymorphism) might have indirect downstream effects on the reward system. The aim of the present study was to examine whether COMT deletion affects reinforcing effects of cocaine in mice. The study was conducted in male mice with homozygous COMT deletion as well as their C57BL/6J wild-type littermates. Animals were trained to nose-poke to receive response-contingent intravenous infusions of cocaine (0.3 mg/kg per infusion; final schedule of reinforcement - fixed ratio (FR) 3 time out 30 s). Following the initial acquisition phase, cocaine self-administration dose-effect functions (0.03, 0.1, 0.3, 1, and 3 mg/kg per infusion) were determined under FR3 and progressive ratio (PR) schedules of reinforcement. Cocaine dose-dependently maintained responding under FR3 and PR schedule of reinforcement when the unit dose of cocaine was varied across the sessions. The total cocaine intake did not differ in COMT deletion mice and wild-type mice. The results of this study suggest that individual differences in COMT activity do not affect primary reinforcing effects of cocaine in mice.
Subject(s)
Catechol O-Methyltransferase/deficiency , Cocaine/administration & dosage , Reinforcement, Psychology , Animals , Catechol O-Methyltransferase/genetics , Dose-Response Relationship, Drug , Male , Methionine/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Polymorphism, Genetic , Valine/geneticsABSTRACT
Glutamate, the main excitatory neurotransmitter in the mammalian CNS, acts via ionotropic and metabotropic receptors. Results from in vitro studies demonstrating tight interactions between ionotropic NMDA receptors and subtype 5 metabotropic glutamate receptors (mGlu5) have shown that blockade of mGlu5 receptors increases the behavioral effects of NMDA receptor antagonists. The aim of the present work was to study the actions of the highly selective mGlu5 receptor antagonist MTEP alone and in combination with MK-801, a blocker of the NMDA receptor-associated ion channel, on performance of a delayed selection task (a test of working memory) in rats. MK-801 (0.1 mg/kg) induced a specific impairment to working memory, with proactive interference (degradation of the ability to remember current information because of the effects of previously learned material). Administration of MTEP (5.0 mg/kg) combined with both solvent and with MK-801 had no significant effects, demonstrating the small or nonexistent involvement of mGlu5 receptors in the mechanisms of working memory.
Subject(s)
Behavior, Animal/physiology , Memory, Short-Term/physiology , N-Methylaspartate/pharmacology , Receptors, Metabotropic Glutamate/metabolism , Animals , Behavior, Animal/drug effects , Dizocilpine Maleate/pharmacology , Male , Memory, Short-Term/drug effects , Rats , Rats, Wistar , Receptor, Metabotropic Glutamate 5 , Receptors, Metabotropic Glutamate/antagonists & inhibitorsSubject(s)
Drug Discovery/methods , Excitatory Amino Acid Antagonists/pharmacology , Nicotinic Antagonists/pharmacology , Smoking/drug therapy , Smoking/psychology , Tobacco Use Disorder/drug therapy , Tobacco Use Disorder/psychology , Drug Discovery/trends , Excitatory Amino Acid Antagonists/chemistry , Excitatory Amino Acid Antagonists/therapeutic use , Humans , Nicotine/pharmacology , Nicotinic Antagonists/chemistry , Nicotinic Antagonists/therapeutic use , Receptors, Nicotinic/physiology , RewardABSTRACT
Glutamate, major excitatory neurotransmitter in mammalian CNS, acts via ionotropic and metabotropic receptors. In agreement with the results of in vitro studies that pointed at close interactions between ionotropic NMDA and metabotropic glutamate mGlu5 receptors, blockade ofmGlu5 receptors was reported to enhance behavioral effects of NMDA receptor channel blockers. The present study aimed to study the effects of a highly selective mGluR5 antagonist MTEP, alone and in combination with NMDA receptor channel blocker MK-801, in rats trained to perform a delay-non-match-to-position task (working memory test). Acute administration of MK-801 (0.1 mg/kg) produced specific working memory impairment expressed as proactive interference (poor performance in the current trial due to the interfering influence of the experience in past trials). However, administration of MTEP (5.0 mg/kg), either alone or in combination with MK-801, had no appreciable effects. While these data clearly indicate little or no involvement of mGlu5 receptors in the mechanisms of working memory, present results demonstrate a robust experimental approach to study cognitive deficits associated with psychotomimetic drug treatment.
Subject(s)
Behavior, Animal/physiology , Memory, Short-Term/physiology , N-Methylaspartate/pharmacology , Receptors, Metabotropic Glutamate/metabolism , Animals , Behavior, Animal/drug effects , Dizocilpine Maleate/pharmacology , Male , Memory, Short-Term/drug effects , Rats , Rats, Wistar , Receptor, Metabotropic Glutamate 5 , Receptors, Metabotropic Glutamate/antagonists & inhibitorsABSTRACT
The actual time-course of morphine antinociception is shorter than what would be predicted from its elimination kinetics, suggesting the presence of an acute tolerance phenomenon. Since antagonists acting at NMDA subtype of glutamate receptors were repeatedly shown to prolong acute morphine antinociception, acute tolerance may be attributed to hyperactivity of NMDA receptors. The ability of various site-selective NMDA receptor antagonists to affect morphine antinociception (tail-flick test) was assessed in mice 30 and 120 min after acute morphine challenge. Competitive NMDA receptor antagonist 3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid (D-CPPene) (SDZ EAA 494; 0.1-1 mg/kg), low-affinity channel blockers 1-amino-3,5-dimethyl adamantane (memantine) (1-10 mg/kg) and 1-amino-1,3,3,5,5-pentamethyl-cyclohexan hydrochloride (MRZ 2/579) (1-10 mg/kg), glycine site antagonists 5-nitro-6,7-dichloro-1, 4-dihydro-2,3-quinoxalinedione (ACEA-1021) (5 or 10 mg/kg) and 8-chloro-4-hydroxy-1-oxo-1,2-dihydropyridaliono(4, 5-b)quinoline-5-oxide choline salt (MRZ 2/576) (1-10 mg/kg) were administered intraperitoneally (i.p.) 15 or 30 min prior to the tail-flick test (i.e., interval between injections of morphine and NMDA receptor antagonist was either 0-15 or 90-105 min). ACEA-1021, MRZ 2/576 and to the lesser extent, memantine and MRZ 2/579 enhanced morphine antinociception when tests were conducted 120 but not 30 min post-morphine. D-CPPene potentiated morphine antinociception irrespective of the interval between morphine administration and the tail-flick test. The results suggest that NMDA receptor antagonists may restore analgesic activity of morphine in acutely tolerant mice.
Subject(s)
Analgesics/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Morphine/pharmacology , Piperazines/pharmacology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Drug Synergism , Drug Therapy, Combination , Drug Tolerance , Glutamic Acid/metabolism , Male , Memantine/pharmacology , Mice , Morphine/administration & dosageABSTRACT
Current perspectives on the clinical use of NMDA receptor antagonists infer repeated administration schedules for the management of different pathological states. The development of tolerance and cross-tolerance between different NMDA receptor antagonists may be an important factor contributing to the clinical efficacy of these drugs. The present study aimed to characterize the development of tolerance and cross-tolerance to the ability of various site-selective NMDA receptor antagonists to produce a decrement of operant responding (multiple extinction 9 s fixed-interval 1-s schedule of water reinforcement). Acute administration of D-CPPen (SDZ EAA 494; 1-5.6 mg/kg), dizocilpine (MK-801; 0.03-0.3 mg/kg), memantine (0.3-17 mg/kg), ACEA-1021 (10-56 mg/kg), and eliprodil (1-30 mg/kg) differentially affected operant responding. Both increases and decreases in response rates and accuracy of responding were observed. Repeated preexposure to D-CPPen (5.6 mg/kg, once a day for 7 days) attenuated a behavioral disruption produced by an acute challenge with D-CPPen or ACEA-1021, but potentiated the effects of dizocilpine, memantine, and eliprodil. Based on the present results, one can suggest that the repeated administration of a competitive NMDA receptor antagonist differentially affects the functional activity of various sites on NMDA receptor complex.
Subject(s)
Conditioning, Operant/drug effects , Excitatory Amino Acid Antagonists/pharmacology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Depression, Chemical , Dizocilpine Maleate/pharmacology , Dose-Response Relationship, Drug , Drug Tolerance , Male , Memantine/pharmacology , Piperidines/pharmacology , Psychomotor Performance/drug effects , Rats , Rats, Wistar , Receptors, Glycine/drug effects , Reinforcement Schedule , WaterABSTRACT
NMDA receptor antagonists have been reported to affect learned behaviors conditioned with abused drugs, with the outcome dependent, in part, on the class of NMDA receptor antagonist used. The present study tested the ability of various site-selective NMDA receptor antagonists to modify cocaine-conditioned motor activity. Two procedures were used for independently assessing drug effects on spontaneous activity and expression of cocaine-conditioned behavior. In the conditioning experiments, rats were administered i.p. injections of cocaine (30 mg/kg) or saline paired with distinctive environments. Spontaneous horizontal activity was dose-dependently enhanced by dizocilpine (0.03-0.3 mg/kg) and memantine (1-30 mg/kg), but not by D-CPPene (3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid; SDZ EAA 494; 1-10 mg/kg), ACEA-1021 (5-nitro-6,7-dichloro-1,4-dihydro-2, 3-quinoxalinedione; 3-56 mg/kg), or eliprodil (3-30 mg/kg). Higher doses of memantine, D-CPPene (1-10 mg/kg), eliprodil (3-30 mg/kg), or ACEA-1021 reduced vertical activity. Following five cocaine-environment pairings, rats displayed significant increases in motor activity when exposed to the cocaine-paired environment. The following antagonists were administered prior to the conditioning test: dizocilpine (MK-801; 0.03-0.1 mg/kg), memantine (1-10 mg/kg), D-CPPene (0.3-3 mg/kg), ACEA-1021 (3-10 mg/kg), and eliprodil (1-10 mg/kg). Of these, memantine, ACEA-1021 and, to the lesser degree, eliprodil attenuated expression of cocaine-conditioned motor activity at doses that did not significantly affect spontaneous motor activity. These results show that cocaine-conditioned behaviors can be selectively modulated by some, but not all, NMDA receptor antagonists.
Subject(s)
Cocaine/pharmacology , Conditioning, Operant/physiology , Excitatory Amino Acid Antagonists/pharmacology , Motor Activity/drug effects , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Dizocilpine Maleate/pharmacology , Dose-Response Relationship, Drug , Male , Memantine/pharmacology , Piperazines/pharmacology , Piperidines/pharmacology , Quinoxalines/pharmacology , Rats , Rats, WistarABSTRACT
The present study assessed the ability of voltage-sensitive calcium channel (VSCC) blockers to affect the behavioral effects of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, dizocilpine, in male Wistar rats. Dizocilpine produced dose-dependent increases in locomotor activity. Nimodipine, verapamil, and flunarizine suppressed dizocilpine-facilitated vertical activity, while horizontal activity was attenuated by verapamil and nimodipine but not flunarizine. Repeated dizocilpine injections resulted in the development of sensitization to its locomotor stimulating properties. Development of sensitization was not context specific, and was observed following repeated exposures to 0.1 but not 0.056 or 0.3 mg/kg of dizocilpine. Nimodipine retarded the development of sensitization to dizocilpine's stimulating effects on horizontal activity, while verapamil suppressed sensitization to the vertical stimulating effects of dizocilpine. Flunarizine had no significant effects on sensitization to dizocilpine's locomotor stimulating properties. In rats trained to discriminate between injections of 0.056 mg/kg of dizocilpine and vehicle, none of the tested VSCC blockers was able to completely antagonize the discriminative stimulus properties of dizocilpine. Nimodipine, when administered in combination with the training dose of dizocilpine, modestly decreased the dizocilpine-lever selection. Dizocilpine dose dependently decreased the self-determined stimulation threshold implanted in rats with electrodes into the ventral tegmental area. Nimodipine exhibited some tendency to block the facilitating effects of dizocilpine, while verapamil and flunarizine had no effects. In summary, in the present experiments VSCC blockers exerted only modest interactions with the behavioral effects of dizocilpine, and it is unlikely that VSCC blockers have remarkable potential as adjunct treatment aimed at correcting the negative side effects of NMDA receptor antagonists (e.g., dizocilpine).
Subject(s)
Behavior, Animal/drug effects , Calcium Channel Blockers/pharmacology , Dizocilpine Maleate/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Animals , Calcium Channels, P-Type/drug effects , Discrimination Learning/drug effects , Flunarizine/pharmacology , Generalization, Stimulus/drug effects , Male , Motor Activity/drug effects , Nimodipine/pharmacology , Rats , Rats, Wistar , Self Stimulation , Verapamil/pharmacologyABSTRACT
Mice were subjected to two successive treatment protocols: first with NMDA receptor channel blockers (14 days, once a day) and second with morphine (5 mg/kg, 8 days, once a day). Treatment with the higher doses of dizocilpine (1 mg/kg), memantine (30 mg/kg), and MRZ 2/576 (30 mg/kg) upon discontinuation revealed only minor behavioral abnormalities attributable to the state of withdrawal. Following repeated administration of low-dose morphine, tolerance to morphine analgesia developed in mice preexposed to dizocilpine (1 mg/kg but not 0.3 mg/kg) but not memantine (10 and 30 mg/kg), MRZ 2/579 (10 and 30 mg/kg), or saline. There were no signs of morphine dependence in any treatment group. Overall, the present study found only minor effects of the subchronic administration of high doses of NMDA receptor channel blockers, suggesting that clinical use of NMDA receptor channel blockers such as memantine will not be accompanied by increased propensity to induction of morphine tolerance and dependence.
Subject(s)
Analgesics, Opioid/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Morphine Dependence/psychology , Morphine/pharmacology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Cyclopentanes/pharmacology , Dizocilpine Maleate/pharmacology , Drug Tolerance , Interpersonal Relations , Male , Memantine/pharmacology , Mice , Reaction Time/drug effectsABSTRACT
Our previous report suggested that antagonists acting at NMDA receptors attenuate discriminative stimulus effects of naloxone in morphine dependent rats. Nitric oxide (NO) is a putative second messenger which mediates NMDA receptor activation. The present study evaluated behavioral effects of NO synthase inhibitor, 7-nitroindazole in morphine-dependent rats trained to discriminate 0.1 mg/kg naloxone from saline. 7-Nitroindazole did not significantly affect naloxone's discriminative stimulus effects but decreased naloxone-induced weight loss and abolished expression of several withdrawal signs--diarrhea, scream on touch, tremor and 'wet dog'-like shaking suggesting different mechanisms for subjective and somatic components of opioid withdrawal.
Subject(s)
Discrimination Learning/drug effects , Indazoles/pharmacology , Morphine/pharmacology , Naloxone/pharmacology , Substance Withdrawal Syndrome/etiology , Analgesics, Opioid/pharmacology , Animals , Body Weight/drug effects , Drug Interactions , Enzyme Inhibitors/pharmacology , Male , Maze Learning , Narcotic Antagonists/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Rats , Rats, Wistar , Substance-Related Disorders/etiologyABSTRACT
The study was dedicated to evaluation of discriminative stimulus properties of opiate withdrawal syndrome precipitated by naloxon. The possibility of naloxon-appropriate reaction significantly increased in a dose-dependent manner (0-1.0 mg/kg, ED50 = 0.03 mg/kg) and was observed during the period of morphine withdrawal (8-96 h, peak at 24 h). Naloxone stimulus effects were antagonized by morphine (10-100.mg/kg), thus providing the experimental evidence for competitive and saturatable nature of interaction with opiate receptors. The probability of naloxone-appropriate reaction decreased during administration of the conditioned stimulus associated with morphine injection. Ligands of peripheral opiate receptors failed to either substitute for naloxone (methylnaloxon, 0.1-3.0 mg/kg) or attenuate naloxone stimulus effects (loperamide, 1-30 mg/kg).
Subject(s)
Discrimination Learning/drug effects , Dissociative Disorders/chemically induced , Maze Learning/drug effects , Morphine Dependence/physiopathology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Animals , Conditioning, Classical/drug effects , Conditioning, Classical/physiology , Discrimination Learning/physiology , Dissociative Disorders/physiopathology , Dose-Response Relationship, Drug , Male , Maze Learning/physiology , Morphine/adverse effects , Narcotics/adverse effects , Rats , Rats, Wistar , Substance Withdrawal Syndrome/etiology , Substance Withdrawal Syndrome/physiopathologyABSTRACT
Glutamate receptors are implicated in the development and expression of drug dependence. Substantial experimental evidence suggests that antagonists acting at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors attenuate the severity of opioid withdrawal. However, it is less clear whether opioid withdrawal can be potentiated by agonists of glutamate receptors. The present study evaluated the behavioural effects of various agonists of glutamate receptors, as well as a nitric oxide (NO) donor, in morphine-dependent rats trained to discriminate 0.1 mg/kg of naloxone from saline. None of the following drugs produced appreciable levels of naloxone-like responding (substitution tests) or potentiated the discriminative stimulus effects of naloxone: NMDA (3-56 mg/kg), glycine (100-1000 mg/kg), glutamate (1000-3000 mg/kg), kainate (0.3-3 mg/kg), isosorbide dinitrate (30-300 mg/kg). Nevertheless, expression of some morphine withdrawal-like somatic and behavioural signs ('wet-dog'-like shaking, scream on touch, ptosis, tremor, chewing, weight loss) was facilitated by NMDA, glycine, and isosorbide dinitrate. These results suggest that, compared to somatic symptoms, subjective effects of opioid withdrawal (as reflected by discriminative stimulus effects) are not mimicked by direct activation of glutamate receptors.
Subject(s)
Behavior, Animal/drug effects , Excitatory Amino Acid Agonists/pharmacology , Morphine Dependence/psychology , Receptors, Glutamate/drug effects , Animals , Brain Chemistry , Discrimination, Psychological/drug effects , Dose-Response Relationship, Drug , Glutamic Acid/pharmacology , Glycine/metabolism , Isosorbide Dinitrate/pharmacology , Kainic Acid/pharmacology , Male , N-Methylaspartate/pharmacology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Nitric Oxide Donors/pharmacology , Rats , Rats, Wistar , Receptors, N-Methyl-D-Aspartate/agonistsABSTRACT
The present study assessed the ability of various site-selective N-methyl-D-aspartate (NMDA) receptor antagonists to affect the discriminative stimulus properties of naloxone in morphine-dependent rats. Adult male Wistar rats were trained to discriminate 0.1 mg/kg of s.c. naloxone from saline using a Y-maze shock-avoidance procedure. Naloxone-appropriate responding was exhibited as a function of naloxone dose (0.01-1.0 mg/kg, ED50 = 0.03 mg/kg) and was also observed when morphine treatment temporarily was discontinued (8-96 hr, peak at 24 hr). Discriminative stimulus effects of naloxone (0.1-3.0 mg/kg) were antagonized by morphine (10-100 mg/kg). Ligands of peripheral opioid receptors failed to either substitute for naloxone (methylnaloxone, 0.1-3.0 mg/kg) or attenuate naloxone's stimulus effects (loperamide, 1-30 mg/kg). In rats treated with the training dose of naloxone, administration of dizocilpine (0.03-0.3 mg/kg) and D-CPPene (1-10 mg/kg) decreased levels of naloxone-appropriate responding, whereas memantine (1-30 mg/kg), ACEA-1021 (10 and 50 mg/kg) and eliprodil (3-30 mg/kg) seemed to have little or no effects. Meanwhile, all NMDA receptor antagonists produced a decrease in the occurrence of two or more of the following opioid withdrawal signs: weight loss, forelimb tremor, ptosis, diarrhea and "wet-dog"-like shaking. Additionally, dizocilpine (0.1 mg/kg), D-CPPene (5.6 mg/kg) and ACEA-1021 (50 mg/kg) but not memantine (10 mg/kg) or eliprodil (30 mg/kg) significantly reduced the naloxone-appropriate escape area selection when administered during the period of suspended morphine treatment 24 hr after the last morphine injection. Thus, NMDA receptor antagonists appear to inhibit the discriminative stimulus effects of both naloxone-precipitated and spontaneous morphine withdrawal, and this ability depends on the type of antagonist applied.